Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition

被引：50

作者：

Fernandez de Larrea, Carlos

Teresa Cibeira, Maria

Elena, Montserrat ^{[2
]}

Ignacio Arostegui, Juan ^{[3
]}

Rosino, Laura

Rovira, Montserrat

Filella, Xavier ^{[2
]}

Yaguee, Jordi ^{[3
]}

Blade, Joan ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Serv Hematol, Dept Hematol, E-08036 Barcelona, Spain

[2] Hosp Clin Barcelona, Dept Biochem, E-08036 Barcelona, Spain

[3] Hosp Clin Barcelona, Dept Immunol, E-08036 Barcelona, Spain

来源：

BLOOD | 2009年 / 114卷 / 24期

关键词：

PLUS THALIDOMIDE; ELDERLY-PATIENTS; PREDNISONE; MELPHALAN; BORTEZOMIB; THERAPY; DEXAMETHASONE;

D O I：

10.1182/blood-2009-06-224832

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The prevalence of an abnormal serum free light chain (FLC) ratio in 34 patients with multiple myeloma in complete response (CR) after hematopoietic stem cell transplantation was studied. Fourteen of 34 patients (41.2%) showed an abnormal FLC ratio. The frequency of abnormal FLC ratio in patients with or without oligoclonal bands was 72.7% versus 26%, respectively (P = .023). The median value of FLC ratio was 2.55 (95% confidence interval, 1.89-3.20) in patients with oligoclonal bands versus 0.87 (95% confidence interval, 0.70-1.04) for those with no oligoclonal bands (P = .011). This is the first report showing that the presence of oligoclonal bands in patients with multiple myeloma in CR frequently results in an abnormal FLC ratio. Because an oligoclonal immune response is associated with a good outcome, our results question the current definition of stringent CR and support that the prognostic impact of oligoclonal bands should be also assessed on multivariate analysis. (Blood. 2009; 114: 4954-4956)

引用

页码：4954 / 4956

页数：3

共 18 条

[11] Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma [J].

Lacy, Martha Q. ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Hayman, Suzanne R. ;

Geyer, Susan ;

Kabat, Brian ;

Zeldenrust, Steven R. ;

Kumar, Shajiku ;

Greipp, Philip R. ;

Fonseca, Rafael ;

Lust, John A. ;

Russell, Stephen J. ;

Kyle, Robert A. ;

Witzig, Thomas E. ;

Bergsagel, P. Leif ;

Stewart, A. Keith ;

Rajkumar, S. Vincent .

MAYO CLINIC PROCEEDINGS, 2007, 82 (10) :1179-1184

[12] Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma [J].

Mark, Tomer ;

Jayabalan, David ;

Coleman, Morton ;

Pearse, Roger N. ;

Wang, Y. Lynn ;

Lent, Richard ;

Christos, Paul J. ;

Lee, Joong W. ;

Agrawal, Yash P. ;

Matthew, Susan ;

Ely, Scott ;

Mazumdar, Madhu ;

Cesarman, Ethel ;

Leonard, John P. ;

Furman, Richard R. ;

Chen-Kiang, Selina ;

Niesvizky, Ruben .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (05) :654-660

[13] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial [J].

Palumbo, A ;

Bringhen, S ;

Coravito, T ;

Merla, E ;

Capporella, V ;

Callea, V ;

Cangialosi, C ;

Grasso, M ;

Rossini, F ;

Galli, M ;

Catalano, L ;

Zamagni, E ;

Petrucci, MT ;

De Stefano, V ;

Ceccarelli, M ;

Ambrosini, MT ;

Avonto, I ;

Falco, P ;

Ciccone, G ;

Liberati, AM ;

Musto, P ;

Boccadoro, M .

LANCET, 2006, 367 (9513) :825-831

[14] Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network [J].

Palumbo, Antonio ;

Falco, Patrizia ;

Corradini, Paolo ;

Falcone, Antonietta ;

Di Raimondo, Francesco ;

Giuliani, Nicola ;

Crippa, Claudia ;

Ciccone, Giovannino ;

Omede, Paola ;

Ambrosini, Maria Teresa ;

Gay, Francesca ;

Bringhen, Sara ;

Musto, Pellegrino ;

Foa, Robin ;

Knight, Robert ;

Zeldis, Jerome B. ;

Boccadoro, Mario ;

Petrucci, Maria Teresa .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4459-4465

[15] Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 [J].

Pineda-Roman, Mauricio ;

Zangari, Maurizio ;

Haessler, Jeff ;

Anaissie, Elias ;

Tricot, Guido ;

van Rhee, Frits ;

Crowley, John ;

Shaughnessy, John D., Jr. ;

Barlogie, Bart .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (06) :625-634

[16] Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up [J].

Popat, Rakesh ;

Oakervee, Heather E. ;

Hallam, Simon ;

Curry, Nicola ;

Odeh, Liz ;

Foot, Nicola ;

Esseltine, Dixie-Lee ;

Drake, Mary ;

Morris, Curly ;

Cavenagh, Jamie D. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) :512-516

[17] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J].

San Miguel, Jesus F. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Dimopoulos, Meletios A. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Petrucci, Maria T. ;

Palumbo, Antonio ;

Samoilova, Olga S. ;

Dmoszynska, Anna ;

Abdulkadyrov, Kudrat M. ;

Schots, Rik ;

Jiang, Bin ;

Mateos, Maria-Victoria ;

Anderson, Kenneth C. ;

Esseltine, Dixie L. ;

Liu, Kevin ;

Cakana, Andrew ;

van de Velde, Helgi ;

Richardson, Paul G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09) :906-917

[18] Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation [J].

Zent, CS ;

Wilson, CS ;

Tricot, G ;

Jagannath, S ;

Siegel, D ;

Desikan, KR ;

Munshi, N ;

Bracy, D ;

Barlogie, B ;

Butch, AW .

BLOOD, 1998, 91 (09) :3518-3523

← 1 2 →